History shows investors should stick to profitable companies if Fed tightens inflation action, Jim Cramer says

History shows investors should stick to profitable companies if Fed tightens inflation action, Jim Cramer says


CNBC’s Jim Cramer on Thursday advised investors to invest in profitable companies if the Federal Reserve institutes a half-point double rate hike, using an analysis of the Fed’s last double rate hike and its aftermath in 2000.

“We know what works when the Fed tightens aggressively. The lesson of 2000 is to stick with profitable companies with real products or services that also have meaningful dividends and buybacks, and to sell the rest,” he said.

The “Mad Money” host’s comments come after traders predicted half-point rate hikes in May and June in response to Federal Reserve Chairman Jay Powell’s pledge on Monday to take strong action against surging inflation.

The Dow Jones Industrial Average rose 1% on Thursday while the S&P 500 gained 1.4%. The Nasdaq Composite climbed 1.9%.

Cramer noted that when then Fed Chair Alan Greenspan implemented a double rate hike in May 2020, the dotcom bubble had burst two months earlier. The Fed had already raised interest rates five times over the previous 11 months, with the May interest rate concluding the tightening cycle, he said.

The Nasdaq lost 78% of its value from its peak in March of that year to October 2002, with 60% of the loss happening after Greenspan implemented a double rate hike, according to Cramer. The S&P 500 fell 50% from its peak with almost 90% of its decline coming after the rate hike while the Dow Jones Industrial Average went down 39% from its high with 80% of the decrease coming after the hike, Cramer said.

Some winners included healthcare, energy and financial stocks, while tech stocks plummeted due to the burst of the dotcom bubble, he added.

However, the host reminded viewers that there are outside factors that make both the current markets and the markets in 2000 unique and not directly comparable, including the current Russia-Ukraine war and the recession in the early 2000s.

“I don’t think we’re watching a one-to-one replay of the dotcom collapse. … But it wouldn’t surprise me if the averages experience more pain between now and the next Fed meeting in early May, especially the unprofitable companies in the tech-heavy Nasdaq,” he said.

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer Twitter – Facebook – Instagram

Questions, comments, suggestions for the “Mad Money” website? [email protected]





Source

E.l.f. Beauty posts earnings beat, raises full-year guidance
Business

E.l.f. Beauty posts earnings beat, raises full-year guidance

Elf Beauty cosmetics Courtesy: e.l.f Beauty E.l.f. Beauty reported a huge earnings beat Wednesday and raised its guidance for the fiscal year. E.l.f. stock was up as much as 15% in after-hours trading before losing the majority of those gains. Here’s what the company reported for the third fiscal quarter, compared with analyst estimates from […]

Read More
Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs
Business

Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs

NFL Hall of Famer Terrell Owens said Wednesday that the recent snubs of New England Patriots owner Robert Kraft and former coach Bill Belichick from the institution show the system is flawed, and someone needs to be held accountable. “It’s just plain dumb” Owens told CNBC Sport in an interview in San Francisco ahead of […]

Read More
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Business

Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market.  Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]

Read More